Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned phase III trial of inhaled liposomal amikacin (ARIKAYCE) in patients with non-tuberculous mycobacteria (NTM) lung infections

Next Previous
Trial Profile

Planned phase III trial of inhaled liposomal amikacin (ARIKAYCE) in patients with non-tuberculous mycobacteria (NTM) lung infections

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Nontuberculous mycobacterium infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Insmed

Most Recent Events

  • 22 Sep 2014 New trial record
  • 04 Aug 2014 According to an Insmed media release, the company will proceed with this second Phase 3 study which will be designed to confirm, in as short a timeframe as possible, the positive culture conversion results seen in the Phase 2 study and results are expected in 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top